3NK.F ALPHAMAB ONCOLO.DL-000002
- Market cap
- EUR 661M
- P/E
- -
- P/B
- 2.98x
- ROE
- -6.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 3NK.F undervalued?
Graham numberThe Graham number of ALPHAMAB ONCOLO.DL-000002 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ALPHAMAB ONCOLO.DL-000002 fundamental analysis
No fundamental analysis for ALPHAMAB ONCOLO.DL-000002 yet.
ALPHAMAB ONCOLO.DL-000002 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ALPHAMAB ONCOLO.DL-000002
Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China. It offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand. Its product pipeline includes KN026, an anti-human epidermal gr…
Full company profileALPHAMAB ONCOLO.DL-000002 financial statements
ALPHAMAB ONCOLO.DL-000002 annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 146M | 167M | 219M | 640M | 566M |
| Gross Profit | 143M | 123M | 164M | 580M | 503M |
| Operating Income | -402M | -408M | -306M | 114M | -136M |
| EBITDA | - | -256M | -129M | 253M | -41.8M |
| Net Income | -412M | -326M | -211M | 166M | -114M |
| EPS | -0.44 | -0.35 | -0.22 | 0.17 | -0.12 |
| Balance Sheet | |||||
| Total Assets | 2.71B | 2.12B | 2.14B | 2.24B | 2.10B |
| Total Liabilities | 835M | 560M | 465M | 410M | 386M |
| Shareholders' Equity | 1.87B | 1.56B | 1.67B | 1.83B | 1.71B |
| Cash & Short-term Investments | 803M | 1.07B | 1.09B | 1.11B | 259M |
| Cash Flow | |||||
| Operating Cash Flow | -321M | -300M | -203M | 212M | -122M |
| Capital Expenditure | 158M | 130M | 36.2M | 21.8M | 31.6M |
| Free Cash Flow | -479M | -430M | -239M | 191M | -153M |
| Ratios | |||||
| ROE | -22.1% | -20.9% | -12.6% | 9.1% | -6.7% |
| ROA | -15.2% | -15.4% | -9.9% | 7.4% | -5.4% |
| Net Profit Margin | -282.4% | -195.2% | -96.3% | 26.0% | -20.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ALPHAMAB ONCOLO.DL-000002 dividends
ALPHAMAB ONCOLO.DL-000002 has not paid dividends in the last 5 fiscal years.
Who owns ALPHAMAB ONCOLO.DL-000002
- Insiders 50.39%
- Institutions 3.19%
- Public & others 46.42%
- Shares outstanding 965M
- Free float 482M
ALPHAMAB ONCOLO.DL-000002 company profile
- Company name
- ALPHAMAB ONCOLO.DL-000002
- Ticker
- 3NK.F
- ISIN
- KYG0330A1013
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 515
- Fiscal year end
- December
- Address
- No. 175 Fangzhou Road, Suzhou, China, 215127
- Phone
- 86 512 6285 0800
- Website
- alphamabonc.com
About ALPHAMAB ONCOLO.DL-000002
Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China. It offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand. Its product pipeline includes KN026, an anti-human epidermal growth factor receptor 2 (HER2) bispecific monoclonal antibody (BsAb) that is in Phase III clinical trials to treat HER2-positive breast cancer and HER2-positive gastric cancer or gastroesophageal junction cancer; KN046, a BsAb immune checkpoint inhibitor in Phase III clinical trial for the treatment of non-small cell lung cancer (NSCLC), squamous NSCLC, triple-negative breast cancer, and recurrent and metastatic esophageal squamous cell carcinoma; JSKN003, a biparatopic HER2-targeting antibody-drug conjugate (ADC) that is in Phase III clinical trial to treat HER2-expressing advanced or metastatic solid tumors, HER2-low expression breast cancer, platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, and fallopian tube cancer. In addition, the company is developing JSKN016, a bispecific ADC that is in Phase II clinical trial for the treatment of solid tumors, lung cancer, and breast cancer; JSKN022, a bispecific single-domain antibody; JSKN027, a bispecific ADC that is Phase I clinical trial; JSKN021; KN019; and JSKN033, a subcutaneous ADC in Phase I clinical trial to treat HER2-expressing advanced or metastatic solid tumors. The company also develops JSKN029, a pre-clinical stage product for oncology applications. Alphamab Oncology was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.
ALPHAMAB ONCOLO.DL-000002 management
9- Dr. Ting Xu Ph.D.Founder, Executive Chairman & CEO · born 1973
- Ms. Yang LiuCOO & Executive Director · born 1972
- Mr. Fei Wang CPAChief Financial Officer · born 1978
- Dr. Hongwei WangChief Technology Officer
- Mr. Yumin WanVice President of Government Affairs & Public Relations · born 1972
- Dr. Mike Liu M.B.A., Ph.D.Senior Vice President of Business Development · born 1966
- Mr. Jing HanChief Commercial Officer · born 1973
- Ms. Lok Yee Chan A.C.I.S., A.C.S.Joint Company Secretary · born 1990
- Ms. Rui JiangJoint Company Secretary